Cargando…
The application of anticoagulant therapy to sepsis
Since the withdrawal of recombinant-activated protein C, the anticoagulant therapy for sepsis was taken no notice. For instance, the international sepsis guidelines did not share a space for this therapy. However, we can see the signs of change recently. The Surviving Sepsis Campaign Guidelines 2016...
Autores principales: | Thachil, Jecko, Iba, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450244/ https://www.ncbi.nlm.nih.gov/pubmed/28572981 http://dx.doi.org/10.1186/s40560-017-0230-3 |
Ejemplares similares
-
Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017) -
DOACs and “newer” hemophilia therapies in COVID‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020) -
Bleeding complications of anticoagulant therapy in sepsis-induced disseminated intravascular coagulation
por: Iba, Toshiaki
Publicado: (2016) -
Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020) -
Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential
por: Ito, Takashi, et al.
Publicado: (2019)